Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GBD Receives Wellcome Trust Support for Development of New TB Diagnostic

Published: Wednesday, March 06, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Company has received a £2.6m($4.3m) strategic translation award from the Wellcome Trust.

A UK company has received a £2.6m($4.3m) Strategic Translation Award from the Wellcome Trust to progress its development of a new, rapid point-of-care test for the diagnosis of tuberculosis, one of the world’s biggest killers.

Global BioDiagnostics (GBD), based at Sci-Tech Daresbury, Cheshire, UK, and Texas, USA, has received the Wellcome Trust money after completing a proof of concept study of a new technique for the diagnosis of tuberculosis.

The test can detect the bacterium that causes TB in as little as 10 minutes. It is based on technology developed at Texas A&M and Stanford and recently described in Nature Chemistry.

The ultimate goal is to develop an accessible, affordable test that can be used at the point of care level in communities across the developing world.

A benchmark evaluation study undertaken in the US and Peru using fresh sputum from suspected TB patients has proven feasibility of the technique for the rapid diagnosis of TB.

Michael T. Norman, CEO of Global BioDiagnostics, said: “This new funding will support refinements of the assay technology and further product development work culminating in field trials of the diagnostic test and CE registration.

“We hope to develop a test that will enable accurate diagnosis at an earlier stage of infection, while requiring little by way of clinical or technical skill, in a matter of minutes and at a fraction of current costs.”

The new diagnostic test uses technology developed by Dr Jeffrey D Cirillo of Texas A&M Health Science Center College of Medicine, near Houston, and Dr Jianghong Rao of Stanford University, California.

The basic research has taken more than five years and has been funded through an on-going £3m-plus ($5m-plus) grant from the Bill and Melinda Gates Foundation to Texas A&M.

The technology utilizes novel chemical substrates that generate a fluorescent signal when they come into contact with an enzyme produced by the bacterium causing TB. This technology is called Reporter Enzyme Fluorescence, or REF.

The fluorescent signal is easily detected by simple, low cost, portable fluorometers that are commercially available.

The new technique is already generating interest from public health authorities and NGOs active in South Africa, India and the Gulf States.

“We expect to develop our base in the UK at Sci-Tech Daresbury, near Liverpool, so that we can manage all aspects of the business from there, including global logistics and international relationship management,” added Mr Norman.

TB is responsible for the deaths of some 1.4m people every year - or 3,800 people every day, half of them children - and is the world’s eighth biggest killer according to the World Health Organization. In 2009, there were almost 10 million orphan children as a result of the disease.

Sci-Tech Daresbury is a national science and innovation campus between Liverpool and Manchester which is regarded as one of Europe’s leading centers for innovation and business. It assumed official status in April 2012 as one of the UK Government’s flagship Enterprise Zones.

The site is a private-public sector joint venture between property company Langtree, the Science and Technology Facilities Council (STFC) and Halton Borough Council. The Universities of Lancaster, Liverpool and Manchester are active partners on the site.

John Downes, Group Chief Executive of Langtree and director of the Sci-Tech Daresbury Joint Venture Company, said: “Sci-Tech Daresbury’s position at the heart of the UK’s science and business community offers immeasurable assistance to businesses wishing to forge links with key partners such as the Wellcome Trust. We’re delighted to be able to play a role in developing something which might have such an important impact on the lives of millions of people.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!